Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 301–350 of 76231
On July 17, 2026, immediately following receipt of stockholder approval at the Special Meeting, Bari A. Harlam and Susan Lattmann resigned from the Board (the “ Board Resignations ”).
On July 17, 2026, immediately following receipt of stockholder approval at the Special Meeting, Bari A. Harlam and Susan Lattmann resigned from the Board (the “ Board Resignations ”).
Joshua Feldman, the Company’s Chief Financial Officer, and the Company entered into a Transition and Separation Agreement (the “ Feldman Agreement ”), pursuant to which Mr. Feldman agreed to remain with the Company as its Chief Financial Officer through September 4, 2026.
On July 17, 2026, Neuronetics, Inc. (the “Company”) and W. Andrew Macan, who has served as Executive Vice President, Chief Legal Officer, and Corporate Secretary and in various other similar capacities since January 21, 2020, entered into a Separation Agreement (the “Separation Agreement”).
On July 14, 2026, Randall A. Moritz resigned from his role as the Chief Operating Officer of Kingfish Holding Corporation (the “Company”) due to medical reasons effective on that same date.
Barbara Humpton will retire as Chief Executive Officer and as a director of the Company, effective on October 1, 2026
in connection with Mr. Pinkston’s June 23, 2026 termination of employment with the Company.
On July 15, 2026, Maureen J. Rude notified the Company’s Board of Directors of her decision to resign, for personal reasons, from the Company’s Board and the Board of Directors of the Bank, effective immediately.
On July 14, 2026, Lawrence G. Finch notified Everspin Technologies, Inc. (the “Company”) of his resignation from the Company’s board of directors (the “Board”), including as a member of the Board’s audit committee, effective August 4, 2026.
On July 13, 2026, Irene Becklund informed Hims & Hers Health, Inc. (the “Company”) of her intention to resign as Chief Accounting Officer and Principal Accounting Officer, effective as of October 9, 2026.
On July 17, 2026, Lindsay Corporation (the “Company”) announced that Sam Hinrichsen notified the Board of Directors of the Company of his intent to resign from his position as the Company’s Senior Vice President and Chief Financial Officer effective August 31, 2026 (the “Effective Date”).
In connection with the appointment of Ms. O’Donnell-Butner, Mr. Mike Nguyen resigned in his capacity as Chief Compliance Officer of the Company, effective as of July 8, 2026.
the Company accepted the resignations or removals by court order of Lei Zhang as Chief Executive Officer and Executive Director, Meihua Xu as President and Treasurer, and Minming Yang as Company Secretary.
the Company accepted the resignations or removals by court order of Lei Zhang as Chief Executive Officer and Executive Director
the Company accepted the resignations or removals by court order of Lei Zhang as Chief Executive Officer and Executive Director, Meihua Xu as President and Treasurer, and Minming Yang as Company Secretary.
On June 4, 2026, Alejandro Araujo notified TOFLA Megaline Inc. (the “Company”) of his resignation as a member of the Company’s Board of Directors (the “Board”), effective immediately upon delivery of his resignation letter.
Mr. Ajay Kumar Dhadha voluntarily resigned from his positions as Chairman of the Board of Directors and Director of the Company, effective June 30, 2026.
Mr. Guy Ofir voluntarily resigned from his positions as Chief Financial Officer, General Counsel, and Director of the Company, effective July 16, 2026.
On July 14, 2026, Sid Tool Co., Inc., a wholly-owned subsidiary of the Company, and Mr. Dongre entered into an Agreement and Release (the “Transition Agreement”) in connection with Mr. Dongre’s transition from his position as Senior Vice President, General Counsel and Corporate Secretary of the Company to Special Advisor of the Company, effective as of July 20, 2026
Ms. Ludgate’s resignation from the Board was for personal reasons and was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
As reported in the Original Form 8-K, effective as of December 14, 2025 (the “Separation Date”), Craig Tooman agreed by mutual consent to end his employment with Silence Therapeutics plc (the “Company”).
On July 13, 2026, Shlomo Dovrat informed the Board of Directors (the “ Board ”) of Unity Software Inc. (the “ Company ”) of his intention to resign as a member of the Board of the Company.
Effective July 14, 2026, Upwork Inc.’s, or the Company’s, Chief Financial Officer and principal financial officer, Erica Gessert, will take a temporary medical leave.
Effective July 13, 2026, Jeremy Daniel ceased serving as Chief Financial Officer and transitioned to a corporate accounting role with the Company.
Accordingly, Duncan McGillivray will cease serving as the Company’s Chief Operating Officer effective July 24, 2026.
On July 13, 2026, the Board approved the termination of the employment of the Company’s Chief Legal Officer, Jonathan Norling, effective as of a date to be determined by the Company’s chief executive officer.
The directors who ceased to serve were: Andrew R. Cichocki, Paula M. Harris, Linda A. Harty, Paul E. Mahoney, David M. Sagehorn, Spencer S. Stiles, and Roger A. Strauch.
The executive officers who were removed were: Gerald F. Vinci, President, Joseph R. Brinkman, Vice President and Chief Financial Officer, and Herbert G. Hotchkiss, Vice President, General Counsel and Secretary.
The directors who ceased to serve were: Andrew R. Cichocki, Paula M. Harris, Linda A. Harty, Paul E. Mahoney, David M. Sagehorn, Spencer S. Stiles, and Roger A. Strauch.
The executive officers who were removed were: Gerald F. Vinci, President, Joseph R. Brinkman, Vice President and Chief Financial Officer, and Herbert G. Hotchkiss, Vice President, General Counsel and Secretary.
The directors who ceased to serve were: Andrew R. Cichocki, Paula M. Harris, Linda A. Harty, Paul E. Mahoney, David M. Sagehorn, Spencer S. Stiles, and Roger A. Strauch.
The directors who ceased to serve were: Andrew R. Cichocki, Paula M. Harris, Linda A. Harty, Paul E. Mahoney, David M. Sagehorn, Spencer S. Stiles, and Roger A. Strauch.
The executive officers who were removed were: Gerald F. Vinci, President, Joseph R. Brinkman, Vice President and Chief Financial Officer, and Herbert G. Hotchkiss, Vice President, General Counsel and Secretary.
The directors who ceased to serve were: Andrew R. Cichocki, Paula M. Harris, Linda A. Harty, Paul E. Mahoney, David M. Sagehorn, Spencer S. Stiles, and Roger A. Strauch.
The directors who ceased to serve were: Andrew R. Cichocki, Paula M. Harris, Linda A. Harty, Paul E. Mahoney, David M. Sagehorn, Spencer S. Stiles, and Roger A. Strauch.
The directors who ceased to serve were: Andrew R. Cichocki, Paula M. Harris, Linda A. Harty, Paul E. Mahoney, David M. Sagehorn, Spencer S. Stiles, and Roger A. Strauch.
On July 16, 2026, the Company announced that Glenn Reicin, the Company’s Chief Financial Officer, will be stepping down as the Company’s Chief Financial Officer effective as of July 16, 2026 to pursue other career opportunities.
Helen Meates, Chief Financial Officer of PJT Partners Inc. (the “Company”), has informed the Company of her intention to step down from her role as Chief Financial Officer as of October 1, 2026 (the “Effective Date”).
each of the directors of the Company (Patrick J. McEnany; Richard J. Daly; Daniel J. Curran, M.D.; Donald A. Denkhaus; Molly Harper; Tamar Thompson; and David S. Tierney, M.D.) resigned and ceased to be directors of the board of directors of the Company and members of any committee thereof, as applicable.
each of the directors of the Company (Patrick J. McEnany; Richard J. Daly; Daniel J. Curran, M.D.; Donald A. Denkhaus; Molly Harper; Tamar Thompson; and David S. Tierney, M.D.) resigned and ceased to be directors of the board of directors of the Company and members of any committee thereof, as applicable.
each of the directors of the Company (Patrick J. McEnany; Richard J. Daly; Daniel J. Curran, M.D.; Donald A. Denkhaus; Molly Harper; Tamar Thompson; and David S. Tierney, M.D.) resigned and ceased to be directors of the board of directors of the Company and members of any committee thereof, as applicable.
each of the directors of the Company (Patrick J. McEnany; Richard J. Daly; Daniel J. Curran, M.D.; Donald A. Denkhaus; Molly Harper; Tamar Thompson; and David S. Tierney, M.D.) resigned and ceased to be directors of the board of directors of the Company and members of any committee thereof, as applicable.
each of the directors of the Company (Patrick J. McEnany; Richard J. Daly; Daniel J. Curran, M.D.; Donald A. Denkhaus; Molly Harper; Tamar Thompson; and David S. Tierney, M.D.) resigned and ceased to be directors of the board of directors of the Company and members of any committee thereof, as applicable.
each of the directors of the Company (Patrick J. McEnany; Richard J. Daly; Daniel J. Curran, M.D.; Donald A. Denkhaus; Molly Harper; Tamar Thompson; and David S. Tierney, M.D.) resigned and ceased to be directors of the board of directors of the Company and members of any committee thereof, as applicable.
each of the directors of the Company (Patrick J. McEnany; Richard J. Daly; Daniel J. Curran, M.D.; Donald A. Denkhaus; Molly Harper; Tamar Thompson; and David S. Tierney, M.D.) resigned and ceased to be directors of the board of directors of the Company and members of any committee thereof, as applicable.
On July 10, 2026, Sam Martin, Senior Vice President and Chief Financial Officer of Celldex Therapeutics, Inc. (the “Company”), notified the Company of his plans to retire effective on or about March 31, 2027.
On July 13, 2026, Heath Lukatch notified the Board of Directors (the “Board”) of Vaxcyte, Inc. (“the “Company”) of his retirement from the Board, effective as of July 16, 2026.
On July 13, 2026, Mark Murray informed the Board of Directors (the “Board”) of Jones Soda Co. (the “Company”) that he was retiring from the Board effective immediately for personal reasons.
each of the directors of the Company (James R. Porter, Ph.D.; Grant C. Bogle; Michael L. Meyers, M.D., Ph.D.; Christy Oliger; Anna Protopapas; Ron Squarer; Sapna Srivastava, Ph.D.; and Cameron A. Wheeler, Ph.D.) resigned from his or her respective position as a member of the Company’s board of directors
each of the directors of the Company (James R. Porter, Ph.D.; Grant C. Bogle; Michael L. Meyers, M.D., Ph.D.; Christy Oliger; Anna Protopapas; Ron Squarer; Sapna Srivastava, Ph.D.; and Cameron A. Wheeler, Ph.D.) resigned from his or her respective position as a member of the Company’s board of directors
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.